A 58-year-old patient is newly diagnosed with metastatic pan…
A 58-year-old patient is newly diagnosed with metastatic pancreatic ductal adenocarcinoma (PDAC) harboring mutations most commonly seen in PDAC. He has unlimited funds and has asked you to develop a theoretical treatment regimen with high chances of success. Which of the following treatment regimens would be most appropriate to target the molecular driver while also addressing systemic disease?
Read Details